Comparison of therapeutic effects of insulin and glibenclamide in gestational diabetes

Document Type : Original Article


1 Assistant professor, Department of Obstetrics and Gynecology, High Risk Pregnancy Research Center, school of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran.

2 Board of Anesthesiology, Department of Anesthesiology, school of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran.


Introduction: Women with gestational diabetes due to concerns about teratogenicity and neonatal hypoglycemia are rarely treated with sulfonylureas. There is little information about the effects of these drugs in this group of women. This study was performed with the aim to compare the therapeutic effects of glibenclamide and insulin in treatment of gestational diabetes.
Methods: This clinical randomized interventional study was performed on 90 women with gestational diabetes requiring treatment in 2010-2011. Women were randomly assigned to treatment with glibenclamide or insulin. Subcutaneous insulin 20 units twice a day was prescribed and, if needed, increased weekly. In the other group, 2.5 mg glibenclamide orally, once a day was started and if needed increased weekly up to a maximum dose of 20 mg. Treatment goal was fasting blood sugar 60-90 and after the food less than 120 mg/dl. Data were analyzed by SPSS software version 16 and Chi-square, independent t, Fisher exact and Mann-Whitney tests. PResults: Only one of the women in the glibenclamide group required to insulin for controlling blood sugar. There was no significantly difference between two groups in the percentage of infants with macrosomia (0.649), Oligohydramnios (0.304), policitemia (0.304), hypoglycemia (0.325), Polyhydramnios (0.778) and other neonatal complications.
Conclusion: Glibenclamide has equivalent effectiveness with insulin in the treatment of gestational diabetes.


  1. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005; 193(1):118–24.
  2. Durnwald C, Landon MB. Glyburide: The new alternative for treating gestational diabetes?. Am J Obstet Gynecol 2005; 193(1):1–2.
  3. Chmiel-Perzyñska I, Perzyñski A, Wielosz M, Urbañska EM. Hyperglycemia enhances the inhibitory effect of mitochondrial toxins and D,L-homocysteine on the brain production of kynurenic acid. Pharmacol Rep 2007; 59(3):268–73.
  4. Csanyi G, Lepran I, Flesch T, Telegdy G, Szabo G, Mezei Z. Lack of endothelium-derived hyperpolarizing factor (EDHF) up-regulation in endothelial dysfunction in aorta in diabetic rats. Pharmacol Rep 2007; 59(4):447–55.
  5. Szkróbka W, Herman ZS, Okopieñ B. Extralipid effects of hypolipidemic drugs – why do clinical trials weakly support experimental data?. Pharmacol Rep 2007; 59(1):129–33.
  6. Kimber-Trojnar Z, Marciniak B, Leszczyñska-Gorzelak B, Trojnar M, Oleszczuk J. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol Rep 2008; 60(3):308-18.
  7. Reece EA, Homko CJ. Diabetes mellitus in pregnancy. What are the best treatment options? Drug Saf 1998; 18(3):209–20.
  8. Balsells M, Corcoy R, Mauricio D, Morales J, Garcia-Patterson A, Carreras G, et al. Insulin antibody response to a short course of human insulin therapy in women with gestational diabetes. Diabetes Care 1997; 20(7):1172–5.
  9. Weiss PA, Kainer F, Purstner P, Zehetleitner G, Huttner U, Haas J. Anti-insulin antibodies and birth weight in pregnancies complicated by diabetes. Early Hum Dev 1998; 53(2):145–54.
  10. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 2006; 27(8):861–8.
  11. Szewczyk A, Mikolajek B, Pikula S, Nalêcz MJ. Potassium channel openers induce mitochondrial matrix volume changes via activation of ATP-sensitive K_ channel. Pol J Pharmacol 1993; 45(4):437–43.
  12. Groop L, Barzilai N, Ratheiser K, Luzi L, Wahlin-Boll E, Melander A, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991; 14(8):724–7.
  13. Groop L, Luzi L, Melander A, Groop PH, Ratheiser K, Simonson DC, DeFronzo RA. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36(1):1320–8.
  14. DeFronzo RA, Simonson DC. Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals. Diabetes Care 1984; 7(1):72–80.
  15. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13(6): 610–30.
  16. Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991; 165(4Pt1): 807–12.
  17. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 1994; 171(3): 653–60.
  18. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343(16): 1134–8.
  19. Yogev Y, Ben-Haroush A, Chen R, Rosenn B, Hod M, Langer O. Undiagnosed asymptomatic hypoglycemia. Diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol 2004; 104(1): 88–93.
  20. Bertini AM, Silva JC, Taborda W, Becker F, Lemos Bebber FR, Zucco Viesi JM, et al. Perinatal outcomes and the use of oral  hypoglycemic agents. J Perinat Med 2005; 33(6):519–23.
  21. Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. Diabetes Res Clin Pract 2007; 76(3):474–5.
  22. Camelo Castillo W, Boggess K, Stürmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol 2014 Jun;123(6):1177-84.
  23. Kavitha N, De S, Kanagasabai S.Oral Hypoglycemic Agents in pregnancy: An Update.J Obstet Gynaecol India 2013 Apr;63(2):82-7
  24. Berggren EK, Boggess KA. Oral agents for the management of gestational diabetes.Clin Obstet Gynecol 2013 Dec;56(4):827-36.
  25. Ramos GA, Jacobson GF, Kirby RS, Ching JY, Field DR. Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. J Perinatol 2007; 27(5): 262–7.
  26. Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol 2004; 190(5): 1438–9.
  27. Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol 2004; 24(10):617–22.
  28. Holt RIG, Clark P, Parry EC, Coleman MAG. The effectiveness of glibenclamide in women with gestational diabetes. Diabetes, Obesity and Metabolism 2008; 10(10):906–11.
  29. Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. Journal of Obstetrics and Gynaecology Research 2013; 39(6):1147–
  30. Cheng YW, Chung JH, Block-Kurbisch I, Inturrisi M, Caughey AB. Treatment of gestational diabetes mellitus: glyburide compared to subcutaneous insulin therapy and associated perinatal outcomes.J Matern Fetal Neonatal Med. 2012 Apr;25(4):379-84.
  31. Brustman L, Langer O, Scarpelli S, El Daouk M, Fuchs A, Rosenn B. Hypoglycemia in glyburide-treated gestational diabetes: is it dose-dependent?. Obstet Gynecol. 2011 Feb;117(2 Pt 1):349-53.
  32. Kahn BF, Davies JK, Lynch AM, Reynolds RM, Barbour CA.Predictors of glyburide failure in the treatment of gestational diabetes.Obstet Gynecol 2006;107(6):1303–1309.
  33. Rochon M, Rand L, Roth L, Gaddipati S. Glyburide for management of gestational diabetes; risk factors predictive of
  34. failure and associated pregnancy outcomes.Am J ObstetGynecol2006;195(4):1090–1094.